258 related articles for article (PubMed ID: 34926989)
1. Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature.
Kamposioras K; Ntellas P; Nikolaou M; Germetaki T; Gazouli I; Dadouli K; Zarkavelis G; Amylidi AL; Tolia M; Mauri D
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34926989
[TBL] [Abstract][Full Text] [Related]
2. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
Lu Y; Wang W; Wang F
Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
[TBL] [Abstract][Full Text] [Related]
5. Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice.
Patel MA; Kratz JD; Lubner SJ; Loconte NK; Uboha NV
J Clin Oncol; 2022 Aug; 40(24):2751-2762. PubMed ID: 35839430
[TBL] [Abstract][Full Text] [Related]
6. Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature.
de la Fouchardiere C; Decoster L; Samalin E; Terret C; Kenis C; Droz JP; Coutzac C; Smyth E
Cancer Treat Rev; 2021 Nov; 100():102289. PubMed ID: 34583303
[TBL] [Abstract][Full Text] [Related]
7. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer.
Booka E; Kikuchi H; Haneda R; Soneda W; Kawata S; Murakami T; Matsumoto T; Hiramatsu Y; Takeuchi H
Anticancer Res; 2022 Jun; 42(6):2977-2987. PubMed ID: 35641297
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
Li D; Tang L; Hu J; Cao X; He Y
J Cancer Res Clin Oncol; 2023 Mar; 149(3):933-939. PubMed ID: 35751682
[TBL] [Abstract][Full Text] [Related]
11. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
Zhu X; Shanzhou Q; Li D; Pang X; Ma D
BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.
Bockorny B; Pectasides E
Future Oncol; 2016 Aug; 12(15):1833-46. PubMed ID: 27166503
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score.
Leone AG; Petrelli F; Ghidini A; Raimondi A; Smyth EC; Pietrantonio F
ESMO Open; 2022 Feb; 7(1):100380. PubMed ID: 35093742
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update.
Shah MA; Hofstetter WL; Kennedy EB;
J Clin Oncol; 2021 Oct; 39(28):3182-3184. PubMed ID: 34406872
[No Abstract] [Full Text] [Related]
15. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
[TBL] [Abstract][Full Text] [Related]
16. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.
Davidson M; Cafferkey C; Goode EF; Kouvelakis K; Hughes D; Reguera P; Kalaitzaki E; Peckitt C; Rao S; Watkins D; Chau I; Cunningham D; Starling N
Clin Colorectal Cancer; 2018 Sep; 17(3):223-230. PubMed ID: 29980492
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.
Qiu HB
Thorac Cancer; 2020 Dec; 11(12):3419-3421. PubMed ID: 33043992
[No Abstract] [Full Text] [Related]
18. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
Alsina M; Moehler M; Lorenzen S
Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for esophageal cancer: Where are we now and where can we go.
Shoji Y; Koyanagi K; Kanamori K; Tajima K; Ogimi M; Ninomiya Y; Yamamoto M; Kazuno A; Nabeshima K; Nishi T; Mori M
World J Gastroenterol; 2024 May; 30(19):2496-2501. PubMed ID: 38817664
[TBL] [Abstract][Full Text] [Related]
20. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
